Volume | 35 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Royalty Pharma PLC | RPRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
27.33 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
2 | 35 | - | 25.92 - 34.65 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
05:21:38 | 3 | $ 27.34 | USD |
Royalty Pharma PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
16.33B | 597.43M | - | 2.35B | 1.13B | 1.90 | 14.39 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Royalty Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 28.01 | 28.20 | 27.08 | 27.46 | 2,265,257 | -0.68 | -2.43% |
1 Month | 28.06 | 28.99 | 27.08 | 28.04 | 2,781,192 | -0.73 | -2.60% |
3 Months | 30.70 | 30.80 | 27.08 | 28.89 | 2,612,705 | -3.37 | -10.98% |
6 Months | 27.18 | 31.655 | 26.56 | 28.83 | 2,712,730 | 0.15 | 0.55% |
1 Year | 33.21 | 34.65 | 25.92 | 29.20 | 2,506,684 | -5.88 | -17.71% |
3 Years | 40.46 | 47.10 | 25.92 | 35.74 | 2,152,162 | -13.13 | -32.45% |
5 Years | 45.90 | 57.50 | 25.92 | 37.99 | 2,152,476 | -18.57 | -40.46% |
Royalty Pharma Description
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |